UPCC 53422: An Open-Label Phase I Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of RO7443904 in Combination with Glofitamab in Participants with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma The Protocol
Enrolling By Invitation
99 years and younger
All
Phase
1
1 Location
Brief description of study
Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints) Please refer to the protocol Section 3 (Objectives and Endpoints)
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
Updated on
14 Jun 2023.
Study ID: 853191
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
